One year after Liberation of the first Latin American vaccine anti COVID-19, manufactured jointly between Argentina and Mexicothe authorities of the regulatory agencies ANMAT y COFEPRIS they celebrated the regulatory cooperation that allowed to carry out your production.
–
In an act of commemorative characterco-organized by ANMAT and COFEPRISwas held on First anniversary from vaccine batch release against SARS CoV-2 of the British AstraZeneca.
The event, done virtuallyfeatured the participation of authorities of regulatory agencies of others countries of the continentsuch as CanadaCuba, ChileGuatemala, NicaraguaPeru and Uruguay, among other. In the same way, They were present referents of the OPS.
The opening of the meeting was in charge of Manuel Limeres, national administrator of ANMATwho highlighted the work carried out together with COFEPRISwhich resulted in the production of a safe vaccine. For his part, the head of the Mexican agency, Alejandro Svarchemphasized the “regulatory solidarity” among peer agencies to produce “a safe, effective and quality biological product”, while assessing the strategic support from PAHO in the vaccine validation process.
In December 2021, the vaccine produced by mAbxienceat that time, a entirely Argentine capital companyand the Liomont Laboratory of Mexico was included as 11th vaccine on the emergency use list validated by WHO and as the first in Latin America. It was announced that, according to data from the Ministry of Health of Mexico, COFEPRIS leads released more than 100 batches of this vaccinewhich is equivalent to more than 85 million doses distributed in several countries in the region.
–
